프리마켓
로그인 회원가입
LFCR
LFCR
Lifecore Biomedical Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$4.34
+0.01 ▲ +0.23%
🌙 7월 28일 5:16 AM ET (한국 7/28 18:16)
$4.45
+0.11 ▲ +2.53%

라이프코어 바이오메디컬(LFCR) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$163M
스몰캡
P/E
-
배당수익률
없음
52주 위치
13%
저점 +20% · 고점 -52%
애널리스트
매수
C
Fundamental health
vs. 미분류 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 69%
밸류에이션
데이터 부족
재무 안정
Top 51%
Index RUTP/E -EPS (ttm) -1.3Insider Own 9.7%Shs Outstand 37.5MPerf Week -7.46%
Market Cap 0.16BForward P/E -EPS next Y -Insider Trans -Shs Float 33.9MPerf Month -19.48%
Enterprise Value 0.34BPEG -EPS next Q -Inst Own 71.94%Short Float 7.32%Perf Quarter -13.55%
Income -0.04BP/S 1.26EPS this Y -Inst Trans 0.89%Short Ratio 12.37Perf Half Y -49.42%
Sales 0.13BP/B -EPS next 5Y -ROA -15.09%Short Interest 2.48MPerf YTD -46.94%
Book/sh -0.76P/C 7.83EPS past 3/5Y 31.55% 0.55%ROE -76.41%52W High -51.67% ($8.98)Perf Year -41.59%
Cash/sh 0.55P/FCF -Sales past 3/5Y 5.02% -26.24%ROIC -22.83%52W Low 19.72% ($3.62)Perf 3Y -56.99%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -430.88%Gross Margin 31.27%Volatility(W/M) 5.02% 6.45%Perf 5Y -64.25%
Dividend TTM -EV/Sales 2.65Sales Y/Y TTM 0.47%Oper. Margin -9.35%ATR (14) 0.28Perf 10Y -62.65%
Dividend Ex-Date -Quick Ratio 2.41EPS Q/Q 9.42%Profit Margin -34.42%RSI (14) 34.24Recom 1.8
Dividend Gr. 3/5Y -Current Ratio 3.79Sales Q/Q -34.02%SMA20 -8.91% ($4.76)Beta 1.1Target Price $6.83
Payout -Debt/Eq 7.23Earnings 2026/5/6SMA50 -13.94% ($5.04)Rel Volume 0.56Prev Close $4.33
Employees 406LT Debt/Eq 7.16EPS/Sales Surpr. 7.44% 18.47%SMA200 -30.96% ($6.29)Avg Volume(3M) 0.20MPrice $4.34
IPO 1996/2/15Option/Short Yes/YesTrades 1230Volume 111,663Change 0.23%
Quarterly earnings trend SEC filings · USD
23.8
23.11
24.2
24.8
24.11
25.2
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-15M

📊 Lifecore Biomedical Inc (LFCR) Investment Analysis

What kind of company is Lifecore Biomedical Inc?

라이프코어 바이오메디컬(LFCR)
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility

💉 LifeCore Biomedical (LFCR) is a U.S. healthcare company built around two core pillars: contract development and manufacturing of injectables, and the production of injectable hyaluronic acid. The company specializes in aseptic filling and finishing of sterile injectables in syringes, vials, and cartridges, along with complex formulation development. It is a specialized player in the branded and generic pharmaceutical space, leveraging long-cultivated expertise in manufacturing premium-grade injectable hyaluronic acid.

Learn more about Lifecore Biomedical Inc →
Market Cap
$0.2B
Approx. KRW 0.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4254
Employees406people
IPO1996/02/15
Current Price$4.34 ≈ 5,946원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS +7.4% 매출 +18.5%
🔔 Earnings release 2026년 3월 16일 (월) · 장 시작 전 EPS +7.4% 매출 +18.5%

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-9.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-34.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
31.3%
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Top 46%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-76.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-15.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-22.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
7.23
✓ Danger level
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.79
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.41
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$6.83
현재가 대비 +57.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
1
예상 부합
1
예상 하회
0%
상회 비율
-22.5%
평균 서프라이즈
2026.05.06
하회
실적 $-0.43 · 예상 $-0.30 -44.9%
2026.03.16
부합
실적 $-0.16 · 예상 $-0.16 +0.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+31.6%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median 25.4% · Top 44%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+0.6%
평균
My positionMid-range
Low range Average High range
미분류 초소형주 Median 14.6% · Bottom 37%
Past 5-Year Revenue
How much revenue grew over the past 5 years
-26.2%
부진
My positionBottom 25%
Low range Average High range
미분류 초소형주 Median 2.8% · Bottom 12%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-34.0%
부진
My positionBottom 25%
Low range Average High range
미분류 초소형주 Median -2.6% · Bottom 21%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -133%p below the market
LFCR -64.3% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-132.6%p
Significantly behind the market
vs Health Care (XLV)
-88.8%p
Significantly behind the sector average
1-year basis
vs S&P 500
-57.6%p
Significantly behind the market
vs Health Care (XLV)
-61.3%p
Significantly behind the sector average
Rank among peers
5-year return Top 14% Based on 28 peers
1-year return Upper-Mid (50%) Based on 36 peers
Current position within 52-week range
Low (-19.7%p) High (-51.7%p)
Current price is 19.7% above the 52-week low and 51.7% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-53.7%
Annualized volatility
78.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $4.34 below the midline ($4.76). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.207 < Signal -0.165 in negative zone + Hist negative (-0.043). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 34.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 7.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.26x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$6.83 vs. current price +57.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership flow is positive
Institutional modest net buying +0.9% · Short interest moderate 7.3% · Short interest fell -0.6%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+0.9%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 71.9%
Adequate institutional weight
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 9.7%
Meaningful insider stake
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 18.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
7.3%
Moderate
Healthcare 초소형주 Median 3.9%
Past 90 days 📉 -0.6%p decrease
Short interest days to cover
12.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 37.5M주
Float (tradable shares) 33.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding LFCR

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
LFCR LFCR This Stock
$162.8M- - -76.41% - +0.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 라이프코어 바이오메디컬(LFCR)?

라이프코어 바이오메디컬(LFCR) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of LFCR?

The market cap of LFCR is approximately $163M, ranking 4,254 within its sector.

What is the 52-week high and low for LFCR?

LFCR has recorded a 52-week high of $8.98 and a low of $3.62.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.